Synergy Pharmaceuticals Inc  

(Public, NASDAQ:SGYP)   Watch this stock  
Find more results for SGYP
4.30
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.45 - 4.68
Open     -
Vol / Avg. 0.00/2.08M
Mkt cap 430.20M
P/E     -
Div/yield     -
EPS -1.12
Shares 100.05M
Beta -0.10
Inst. own 31%
May 11, 2015
Q1 2015 Synergy Pharmaceuticals Inc Earnings Release
Mar 16, 2015
Q4 2014 Synergy Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -53.83% -66.95%
Return on average equity - -381.39%
Employees 35 -
CDP Score - -

Address

420 Lexington Ave Rm 2012
NEW YORK, NY 10170-2099
United States - Map
+1-212-2970010 (Phone)
+1-212-2970019 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Synergy Pharmaceuticals Inc., (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is engaged in the field of human therapeutics. The Company’s products include plecanatide, SP-333 and FV-100. Plecanatide is a guanylate cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is also developing SP-333, a second generation GC-C receptor agonist for the treatment of inflammatory bowel diseases, such as ulcerative colitis (UC). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for ulcerative colitis (UC), an inflammatory bowel disease. The Company’s subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Officers and directors

Gary S. Jacob Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Patrick H. Griffin M.D. Executive Vice President and Chief medical officer
Age: 60
Bio & Compensation  - Reuters
Bernard F. Denoyer CPA Senior Vice President - Finance, Secretary, IR Contact Officer
Age: 67
Bio & Compensation  - Reuters
Kunwar Shailubhai Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Thomas H. Adams Jr., Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 67
Bio & Compensation  - Reuters
Alan F. Joslyn Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Christopher McGuigan Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Melvin K. Spigelman M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters